NICE says final no to Yondelis for ovarian cancer despite patient access scheme
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal body for England and Wales, has today published final guidance rejecting PharmaMar's Yondelis (trabectedin), to be used in combination with pegylated liposomal doxorubicin hydrochloride, for treating National Health Service patients with relapsed platinum-sensitive ovarian cancer.